Collegium Pharmaceutical (NASDAQ: COLL) insider transactions

In the twelve months to 10 November 2026, executives and directors of Collegium Pharmaceutical reported 12 open-market sales of 143,626 shares ($6.0m) and 0 open-market purchases, by 7 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in Collegium Pharmaceutical shares reported on Form 4
Date	Insider	Role	Transaction	Shares	Price	Held after	Filing
8 June 2026	Santini Gino	Director	Option exercise	+8,700	$16.49	112,483	Form 4
18 May 2026	Freund John Gordon	Director	Open-market sale	−20	$34.05	83,952	Form 4
15 May 2026	Freund John Gordon	Director	Option exercise	+8,700	$16.49	88,099	Form 4
15 May 2026	Freund John Gordon	Director	Open-market sale	−4,127	$34.54	83,972	Form 4
14 May 2026	Bohlin Garen G	Director	Grant or award	+8,741	—	71,000	Form 4
14 May 2026	Santini Gino	Director	Grant or award	+8,741	—	103,783	Form 4
14 May 2026	Freund John Gordon	Director	Grant or award	+8,741	—	79,399	Form 4
14 May 2026	Lurker Nancy	Director	Grant or award	+8,741	—	26,758	Form 4
14 May 2026	Paya Carlos V	Director	Grant or award	+8,741	—	28,323	Form 4
14 May 2026	Balice-Gordon Rita J.	Director	Grant or award	+8,741	—	61,370	Form 4
14 May 2026	Glancy Donovan Michael	Director	Grant or award	+17,482	—	17,482	Form 4
13 May 2026	Lurker Nancy	Director	Open-market sale	−4,500	$35.97	18,017	Form 4
11 May 2026	Bohlin Garen G	Director	Option exercise	+8,700	$16.49	70,959	Form 4
11 May 2026	Bohlin Garen G	Director	Open-market sale	−8,700	$37.18	62,259	Form 4
18 March 2026	Dieter David	EVP & General Counsel	Open-market sale, 10b5-1 plan	−13,976	$34.92	77,071	Form 4
17 March 2026	Dieter David	EVP & General Counsel	Shares withheld for tax	−8,840	$35.72	68,231	Form 4
9 March 2026	Dieter David	EVP & General Counsel	Open-market sale, 10b5-1 plan	−6,224	$36.65	91,047	Form 4
3 March 2026	Dreyer Scott	EVP & Chief Commercial Officer	Open-market sale, 10b5-1 plan	−46,417	$40.36	75,329	Form 4
3 March 2026	Dreyer Scott	EVP & Chief Commercial Officer	Open-market sale, 10b5-1 plan	−3,559	$40.99	71,770	Form 4
10 February 2026	Karnani Vikram	President and CEO	Grant or award	+79,264	—	176,629	Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Collegium Pharmaceutical page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.